Therapy Areas: Diabetes
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
8 October 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) said on Thursday that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug ...
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
6 October 2026 - Mozart Therapeutics Inc, a developer of CD8 Treg network modulators for the treatment of autoimmune disease, announced on Monday the presentation of clinical and preclinical data for ...
Aroa Biosurgery reports significantly improved healing of diabetic foot ulcers in Symphony trial
5 October 2026 - Aroa Biosurgery Limited (ASX:ARX), a New Zealand-based soft tissue regeneration company, on Monday reported positive results from a prospective, multicentre randomised controlled tria...
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
30 September 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) revealed on Wednesday that it has achieved positive 48-week Phase 2b results for EloraTZP, its investigational combination of elo...
Lakewood-Amedex Biotherapeutics reports positive data for clinical candidate Nu-3 in diabetic foot ulcers
29 September 2026 - Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT), a clinical-stage biotechnology company focused on advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials f...
REGENXBIO reports positive three-year durability data for surabgene lomparvovec in diabetic retinopathy
25 September 2026 - Biotechnology company REGENXBIO Inc (Nasdaq:RGNX) on Thursday announced positive long-term follow-up data from the Phase II ALTITUDE study of investigational surabgene lomparvovec ...